Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.580
-0.040 (-2.47%)
Dec 9, 2025, 4:00 PM EST - Market closed
Akebia Therapeutics Employees
Akebia Therapeutics had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$1,243,486
Profits / Employee
-$87,873
Market Cap
419.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181 | 14 | 8.38% |
| Dec 31, 2023 | 167 | -38 | -18.54% |
| Dec 31, 2022 | 205 | -221 | -51.88% |
| Dec 31, 2021 | 426 | 46 | 12.11% |
| Dec 31, 2020 | 380 | 20 | 5.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKBA News
- 8 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Akebia Announces Establishment of Rare Kidney Disease Pipeline - GlobeNewsWire
- 8 days ago - Q32 Bio Sells Complement Inhibitor ADX-097 - PRNewsWire
- 15 days ago - Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire